May 13, 2019
The oral beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat and the anti-amyloid beta protofibril antibody BAN2401, which Eisai is currently developing for early Alzheimer’s disease (AD), have been selected by the Alzheimer’s Clinical Trial Consortium (ACTC) as compounds to be...read more